{"name":"Oncolytics Biotech","slug":"oncolytics","ticker":"ONCY","exchange":"NASDAQ","domain":"oncolyticsbiotech.com","description":"Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.","hq":"Calgary, Alberta, Canada","founded":1999,"employees":"~75","ceo":"Thomas Heineman, M.D., Ph.D.","sector":"Oncology / Oncolytic Virus Immunotherapy","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$123.4M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":13314000,"netIncome":-28759000,"cash":5202000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"Oncolytics Biotech Receives FDA Fast Track Designation for Pelareorep in Combination with Keytruda for Advanced Solid Tumors","summary":"Oncolytics Biotech announced that the US FDA has granted Fast Track designation to pelareorep in combination with Keytruda for the treatment of advanced solid tumors.","drugName":"pelareorep","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Oncolytics Biotech Reports Third Quarter 2023 Financial Results","summary":"Oncolytics Biotech reported its third quarter 2023 financial results, with a net loss of $13.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-31","type":"deal","headline":"Oncolytics Biotech Announces Collaboration with Merck to Develop Pelareorep in Combination with Keytruda","summary":"Oncolytics Biotech announced a collaboration with Merck to develop pelareorep in combination with Keytruda for the treatment of advanced solid tumors.","drugName":"pelareorep","sentiment":"positive"}],"realNews":[{"date":"2026-04-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-04-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-04-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxOakZzRExDVVdLODAtT0FjVGdySE9QWjRvMDY3Z1UzRlNjdU1VTnp3RVhfc2J5bXZ2RTNna05uUlluMVpCN2JWLVJJZG1IZW5ESEYwTkZCeVE2TEphR2VXTzhHa2NoRjRHcVpScDl2bzVMSWRsVjNNeVAxT1J6cFlXZW9BeHBFS2tEQzNLOWc0clZZZE9ncEVySjJnNW5CZGRWOE51RTc5M2V5RU5RZWp6VUdTeG1KRExyeDRPYmREM1ljV29WenNVYWMwQnE4dlJpa01URjVxMW8zdDBLbm1idm90WTZXZ9IB6wFBVV95cUxQVDlZZXloR2tJbUxTMDJXU3JKdG5wU1AwN3NSc0xKN2pGS0tiTmlmMG56NUJWem50bVdhWE51YTk1VTFsLVZJakE5T255akg3YkhJd2Fva2ZLTEhRZXVNcjBQZFN3SmhTLVVFcXJYTm9sOXZ4blIyMWNuNTJtZUo0bzc4aGdDN0JmSzc2THEwZE5IWF9UZWUyci1nV1ZTQjUzdEpJTGpfQ2gzUnRYRFowcmxmSW5ScmFOcnVuR0hqTWFKMWlNU3lFVnN6dHJpWnNIRUtVbUZaLVlXbk1CQlZKQlpTSzJEcTE1MEQw?oc=5","date":"2026-03-26","type":"trial","source":"simplywall.st","summary":"Is It Time To Reassess Oncolytics Biotech (ONCY) After Recent Trial Progress News? - simplywall.st","headline":"Is It Time To Reassess Oncolytics Biotech (ONCY) After Recent Trial Progress News?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5DSmFhNnNGVFJwOEozQ2Q3b0FSTmZwTVg0VG1heVRFMDF0UEJqY0RyY2VNRnE4SEpDckN4aThobkFxOG16OE5QQU9IWG1rQzBzT0toQzI1RWd4eU1TZUZaSDVqeFIzcjZOY3hBdE9R?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Oncolytics Biotech Inc (ONCY) - Stock Titan","headline":"If You Invested $1,000 in Oncolytics Biotech Inc (ONCY)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-25","type":"pipeline","source":"simplywall.st","summary":"Oncolytics Biotech (ONCY) Valuation Check After Recent Share Price Momentum And Conflicting Signals - simplywall.st","headline":"Oncolytics Biotech (ONCY) Valuation Check After Recent Share Price Momentum And Conflicting Signals","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-15","type":"regulatory","source":"simplywall.st","summary":"Oncolytics Biotech (ONCY) Is Up 19.7% After FDA Fast Track For KRAS-Mutant mCRC Regimen - simplywall.st","headline":"Oncolytics Biotech (ONCY) Is Up 19.7% After FDA Fast Track For KRAS-Mutant mCRC Regimen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxNNGVpUFhJZW9tODl4ZFRiMGM5NDljUW9LRHppUVM2bXBVbFhUMEVWX1RCanQ3dWt5WV9URl9zLVVaVVpJa0lIbUNNYTNnRGduRE5iTGoyeUlNSm9zQ2ROSkZDZmQ4QUF3R0cyWTIzcTFBX1BTRXRYLU5kSVBFdnJMNi1CX1dLWm5tdEdoLU5UUVplOFdhUEVuZ1pvX3JnZFRWYVgwY0RmV1JSdWhMZVhSdTBJX3VTZ25EYzhBUkl3NkpyRTdxNXZybXhoZ1NreTZ6RWgxb3FtSVVKSXJLVTRvVEZkME1zS2VKdUFGWVdlZENfUnd3d3owdjBnMkdfdC1y?oc=5","date":"2026-01-27","type":"pipeline","source":"The Globe and Mail","summary":"Hard-to-Treat Cancers: How 2026’s Top Clinical Platforms Are Beating Industry Benchmarks - The Globe and Mail","headline":"Hard-to-Treat Cancers: How 2026’s Top Clinical Platforms Are Beating Industry Benchmarks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxOQWsxaTRKZHdTalhSWlJUYUsyLVpibzZNNzE2SjludWlxay1xQVRIT2lGOVpXUGxDOWZhdVl2UGZJbGhuZUxodk5WWlFzV2h5SXc4SXFWTkxXeDdWUmUxczMwU2I5QnlrOXpwT1BLY0NwNnhyZ3o5M0luVzZLTy12bkU0S0VMS2tocHBTc0I2SjVjbEhvUnYwZnVRRTktMXRKSjgyVXlSbE5qTlRwRmtmWGdPMmdpeUZ2TmNCeERPaXl1SXNieFRGZkNvTHA2Wl9yUmc?oc=5","date":"2026-01-14","type":"patent","source":"PR Newswire","summary":"Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - PR Newswire","headline":"Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxPTDNxQ0JQd2pSLTBOaW5VUVlNOHV4blhGakdoNlgwWDVrMDE3VVh0Q0pDZF9HUkxsZmhEQ2dqSmlyNFVNNXJkRzgyUFBSV1E4S04yVnpaODdzYWpBTXFZblVObFNQVWttWjJld0E2bGd2NFQ0WUN5NXRBVnBZemZaWVdLVkczT2pNX2ljVFNuMllReVdFNjlaZUo3ak1NYVVIUFNrZEMtcWtsMmxZcS1nb1F1bmExU3JNWDlITXZIVzl0MkRZT3cySWlYQXVIb2lmZFI1Z0VKM2pmemwydEtSMg?oc=5","date":"2026-01-08","type":"pipeline","source":"globenewswire.com","summary":"The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech - globenewswire.com","headline":"The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNRFlFSkJ2aE5JVUpPSkRoV1V3c0tyNWZ5dkdlLVRtdWVLLWhNRzBFNklKRjg0R3BSbjFTeFduWWRfMXNRWmlYdWEzQjdOM3A0ZVBPbGZ0ZUFDaTM3X3JzMGpyTV9JcXZKc19qQjlsWGxQRVhHajlRNDY1QjVvek11QnZNT1lPaUVOVnFROTA4VFFfYzZ4V0ZibTRwTm5FTHR1R0xLOTA4cmJnc2tKMTBSQ3lvWjI1c2Q1Z1E?oc=5","date":"2026-01-08","type":"pipeline","source":"AD HOC NEWS","summary":"The Truth About Oncolytics Biotech (ONCY): Hidden Gem Or Total Trap? - AD HOC NEWS","headline":"The Truth About Oncolytics Biotech (ONCY): Hidden Gem Or Total Trap?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPa1U5WXJYRWVHSWl1R3QzYmR6YnQyOE45QVN0SlFWYmpoaHhKcU5VQzdRNU9PWnBXS0w3RGU1UlJzTXgybWo5RHRGSFJDVHl2MFA1dHlMcllxT0RZZUxVTFhNMzBxYkdpV0pFRk9HVWNKTjhDVzJTVEpZQ2s2QUwtR1dkRm9MdXo0ajQ4aVlkVUxERHBzSWg2UFh0Z0NlcWxUOGpFNl9hQXhpSHNBdE1vYjQ1djN0QQ?oc=5","date":"2025-11-17","type":"pipeline","source":"GuruFocus","summary":"Oncolytics Biotech (ONCY) Price Target Raised by HC Wainwright | - GuruFocus","headline":"Oncolytics Biotech (ONCY) Price Target Raised by HC Wainwright |","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQa3RkQ2hIUU10RWVUOEhfOHV0Ykh3ZF9MNGE1TWJUSzN2Ukt4Wi1FbGpWX0VPTWp1NzNweUd3Y3YzcDgydTFjLTBZMkk4NjJ4YUNkb21mUTY2bjJFOEJyYkhoUmR0SUpUTlBQQ0lHUDB6N05LTVl3VnJtRVBlSjRvU2VZcTktUVQ4b0ZKczBUY2VBZzBFNk5sQVlBam9tZkRmXzJkQlFaQkZLcXRDa2xEeW5adnhjQmJPd0Z4OENWN2Z4TUJrWF9EV2FnNVRCOUVZdVE?oc=5","date":"2025-08-08","type":"pipeline","source":"PR Newswire","summary":"Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange - PR Newswire","headline":"Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQOHBhM00yT0tXN3FqQjhrRXJiZVhrcFBEWDZTSHROaEhPak9ra1RnX1h5ZmpPckhvcGFya09TOTR4VUVyc3kwR1BrQlJHMUZkQjMxc0xEd2ppcWRYc3lPbjQ3R1BlWDV3RTRCSWk5bU9BVklJV2NTT1dGTGZlQ0s3RzV3?oc=5","date":"2025-04-11","type":"pipeline","source":"The Pharma Letter","summary":"Oncolytics secures $20 million to advance cancer therapy development - The Pharma Letter","headline":"Oncolytics secures $20 million to advance cancer therapy development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOa3I4U0RYVjY3bmdnQVo3eURXc3hQMnl0U0tlZk9IbEhCUmZDRTdHRUJwT3dKSlFham9VcGczaVo5VFdpa0Zia25pWVlVYXNCUFowWHdoU2o2djFBamloelV0bFZibEFScUUyRzRONUYxcEwzOUpXdGhiQmJ5WjhFUm9Najg3cnlKY09ZWlhHZDZDR19sOXFmLWp6NEs?oc=5","date":"2025-03-10","type":"pipeline","source":"Seeking Alpha","summary":"Oncolytics Biotech Stock: Continuing To Justify The Negativity (NASDAQ:ONCY) - Seeking Alpha","headline":"Oncolytics Biotech Stock: Continuing To Justify The Negativity (NASDAQ:ONCY)","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Oncology","Immunotherapy"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":13314000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-28759000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":5202000,"cashHistory":[],"totalAssets":7582000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}